natgillin/translations-raw huggingface dataset:
said first DNA molecule hybridizes specifically to SEQ ID NO:5 from about nucleotide position 2060 through about nucleotide position 12,208, and wherein said second DNA molecule hybridizes specifically to the reverse complement sequence corresponding to SEQ ID NO:3 from about nucleotide position 1 through about position 2050. 
(ii) se prva navedena DNA molekula specifično hibridizira sa SEQ ID NO: 5 na nukleotidnoj poziciji od oko 2060 do nukleotidne pozicije 12,208, 1 pri čemu spomenuta druga DNA molekula specifično hibridizira obrnuti redoslijed sekvence koja odgovara SEQ ID NO: 3 pozicije nukleotida od oko 1 do oko pozicije 2050.
Compound 70 was obtained from compound 69 and 4-amino-N-thiophen-2ylmethyl-benzamide by method C as a trifluoroacetic acid salt after purification by reverse phase HPLC. 
Spoj 70 se dobiva iz spoja 69 i 4-amino-N-tiofen-2-ilmetil-benzamida pomoću postupka C kao sol trifluoroctene kiseline nakon pročišćavanja pomoću HPLC na reverznoj fazi.
Median survival times for saline-treated control animals and animals receiving Compound 4 (0.5 mg/kg) were 6.7 and 15.6 days, respectively. 
Medijani vremena preživljavanja za kontrolne životinje tretirane fiziološkom otopinom i životinje koje su primile spoj 4 (0,5 mg/kg) su redom 6,7 1 15,6 dana.
A door closer for a door, which is supportable by a stationary support structure, the door being movable between an open door position and a closed door position, the door closer comprising: 
PATENTNI ZAHTJEVI Spojnica za zatvaranje vrata, poželjno staklenih vrata, koju podupire stacionarna potporna struktura, vrata se pomiču između otvorenog položaja i zatvorenog položaja, spojnica za zatvaranje vrata obuhvaća:
The data memorized in error counters 21a-21d and in error location detectors 22a-22d is then transmitted to respective microprocessor 6a, 6b in the form of control signals to indicate the presence, if any, of data transmission errors. 
Memorirani podaci u brojačima grešaka 21a-21d i u detektorima lokacije grešaka 22a-22d se zatim prenose u odnosni mikroprocesor 6a, 6b u obliku upravljačkih signala da ukazu na prisutnost, ako ih ima, grešaka u prijenosu podataka.
The blender container 106 may include a handle 800 and a spout 801 that facilitates the decanting of the contents of the container. 
Posuda mješalice 106 može uključivati dršku 800 i kljun 801 što olakšava izlijevanje sadržaja iz posude.
A method of producing a binding molecule or a functional variant according to the invention is an additional part of the disclosure. The method comprises the steps of a) culturing a host under conditions conducive to the expression of the binding molecule or functional variant thereof, and b) optionally, recovering the expressed binding molecule or functional variant thereof. 
Postupak za proizvodnju molekule za vezanje u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time, da taj postupak uključuje sljedeće korake: a) uzgoj stanice domaćina u skladu s patentnim zahtjevom 7 ili 8 pod uvjetima koji pogoduju eksprimiranju molekule za vezanje, te po izboru, b) rekuperacija eksprimirane molekule za vezanje.
In a further aspect, the invention provides an anti-FGFR3 antibody of the invention for use in depleting cells, such as multiple myeloma cells. 
Anti-FGFR3 antagonističko protutijelo iz bilo kojeg od patentnih zahtjeva 1-10 za uporabu u inhibiciji proliferacije stanica i/ili depleciji stanica multiplog mijeloma.
The process according to claim 9, wherein said purification is carried out by column chromatography. 
Postupak u skladu s patentnim zahtjevom 7, naznačen time što se navedeno pročišćavanje provodi kromatografijom na stupcu.
is a hydrogen atom, a hydroxy group, a C1 to C6 alkoxy group optionally having substituent(s), or a C1 to C6 alkyl group optionally having substituent(s); 
je atom vodika, hidroksigrupa, C1 do C6 alkoksi grupa koja po izboru ima supstituent(e), ili C1 do C6 alkil grupa koja po izboru ima supstituent(e);
X-[(Pro)n-His-Pro-His-Ala-Arg-Ile-Lys]m-Y (S 1) wherein X is H, or an acetyl group or any natural amino acid or sequence of amino acids provided with a free or at least acetyl-derivatized NH2 group; Y is an OH group or an NH2 group or any amino acid or sequence of amino acids with a C-terminal carboxy-amide group; "n" is an integer from 1 to 10 and "m" is an integer from 1 to 3. 
X- [(Pro)n-His-Pro-His-Ala-Arg-Ile-Lys]m- Y (S 1) naznačena time da X je H, ili acetil grupa ili bilo koja prirodna aminokiselina ili sekvenca aminokiselina koja ima slobodnu ili barem acetil-derivatiziranu NH2 skupinu; Y je skupina OH ili NH2 skupina; "n" je cijeli broj od 1 do 10 i "m" je cijeli broj od 1 do 3; i pri čemu se aminokiselinska sekvenca molekule izvedene iz peptida bira iz skupine koja se sastoji od:
a first soluble tumor necrosis factor (TNF) superfamily cytokine domain, 
(1) prvu topljivu citokinsku domenu iz TNF obitelji,
transferring, simultaneously from the K levels of the entry transfer device to the K levels of the entry elevator, of said group of N load; and at an iteration of a rising/descending cycle of the entry elevator, transferring said group of N loads, from the K levels of the entry elevator to the at least one multi-level storage unit under a constraint of depositing of the N loads. 
– transport (72), istodobno na K razina, navedene skupine od N komada robe od ulaznog transportnog uređaja do ulaznog dizala; i – prilikom ponavljanja navedenog ciklusa dizanja i spuštanja, transport (72) navedene skupine od N komada robe, od ulaznog dizala do najmanje jednog višerazinskog skladišnog kompleksa, uz pridržavanje navedenog ograničavanja spremanja N komada robe.
The compound for use according to claim 14, wherein said second active agent is selected from the group consisting of a DNA-hypomethylating agent, a therapeutic antibody that specifically binds to a cancer antigen, a hematopoietic growth factor, a cytokine, an antibiotic, a cox-2 inhibitor, an immunomodulatory agent, an anti-thymocyte globulin, an immunosuppressive agent, and a corticosteroid or a pharmacological derivative thereof or wherein said second active agent is an anti-PDl antibody or an anti-PDLl antibody. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 13, naznačen time što je drugo aktivno sredstvo izabrano iz skupine koja se sastoji kemoterapeutskog sredstva, DNA-hipometilirajućeg sredstva, terapeutskog antitijela koje se specifično veže na antigen raka, hematopoetski faktor rasta, citokin, antibiotik, inhibitor cox-2, imunomodulatorni agens, antimocitni globulin, imunosupresivno sredstvo i kortikosteroid ili farmakološki derivat ili gdje je drugo aktivno sredstvo anti-PD1 antitijelo ili anti-PDL1 antitijelo.
A compound according to claim 6 that is (4-cyclopropyl-piperazin-1-yl)-(4-morpholin-4-ylmethyl-phenyl)-methanone. 
Spoj u skladu sa zahtjevom 6, naznačen time, da je (4-ciklopropil-piperazin-1-il)-(4-morfolin-4-ilmetil-fenil)-metanon.
The incubated tubes are then centrifuged at 3,000 rpm for 30 min and the supernatant removed by suction. 
Inkubirane epruvete su zatim centrifugirane 30 minuta na 3.000 o/min, a supernatant je uklonjen isisavanjem.
In a further aspect the present invention provides a combination (for example for the treatment of COPD, asthma or allergic rhinitis) of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined and one or more agents independently selected from: a non-steroidal glucocorticoid receptor (GR-receptor) agonist; 
Kombinacija spoja sa formulom (I) prema bilo kojem zahtjevu od 1 do 15 ili njegove farmaceutski prihvatljive soli i jednog ili više sredstava koja su neovisno odabrana od: agonist ne-steroidalnog glukokortikoidnog receptora; selektivni agonist BB» adrenoceptora; inhibitor fosfodiesteraze; inhibitor proteaze; glukokortikoid; anti-kolinergijsko sredstvo; modulator funkcije kemokinskog receptora; i inhibitor funkcije kinaze.
Acid addition salts of the free bases of formula I (in either the racemic or optically active form) may be prepared by conventional procedures such as by mixing the amine base in a suitable solvent with the appropriate acid and recovering the salt by evaporation or by precipitation upon adding a nonsolvent for the salt. 
Aditivne soli s kiselinama slobodnih baza formule I. (ili u racemskom ili u optički aktivnom obliku) mogu se napraviti konvencionalnim postupcima kao što je miješanje aminske baze u nekom pogodnom otapalu sa odgovarajućom kiselinom i izoliranje soli isparavanjem ili taloženjem nakon dodavanja neotapala za sol.
the first fragment is a C . difficile toxin A repeating domain fragment; 
() prvi fragment je fragment ponavljajuće domene toksina A 1z bakterije C. difficile;
The reaction mixture was then allowed to warm to room temperature and stirring was continued for 18 hours. 
Reakciona smjesa se zatim ostavi da se zagrije do sobne temperature i miješanje se nastavi još u tijeku 18 sati.
An antibody for use of any one of claims 1-18 or 22-30, a conjugate for use of claim 31 or a pharmaceutical composition of claim 32, for use in a method of treating or preventing a disease or disorder involving cells expressing CLD18A2. 
Protutijelo iz bilo kojeg od patentnih zahtjeva 1 do 5 i/ili konjugat iz patentnog zahtjeva 7 ili farmaceutski sastav iz patentnog zahtjeva 8 za uporabu u metodi za liječenje ili prevenciju bolesti ili poremećaja koji uključuju stanice koje izražavaju CLD18A2.
A liquid long acting injectable formulation for use according to claim 8, wherein the ectoparasite is selected from the group consisting of Ctenocephalides, Rhipicephalus, Dermacentor, Ixodes, Boophilus, Ambylomma, Hyalomma, Sarcoptes, Psoroptes, Otodectes, Chorioptes, Hypoderma, Damalinia, Linognathus, Hematopinus, Solenoptes and mixtures thereof. 
Tekuća injektibilna formulacija s produljenim djelovanjem za uporabu prema zahtjevu 8, naznačena time, da je ektoparazit odabran 12 skupine koju čine: Crenocephalides, Rhipicephalus, Dermacentor, Ixodes, Boophilus, Ambylomma, Hyalomma, Sarcoptes, Psoroptes, Otodectes, Chorioptes, Hypoderma, Damalinia, Linognathus, Hematopinus, Solenoptes i njihove kombinacije.
When the granulate has been dried, it is mixed with 100 g of sodium carboxymethylcellulose, 25 g of silica, 5 g of glycerol palmitostearate and 10 mg of talcum before being subjected to compression to the unit weight of 495 mg/tablet. 
Nakon što je granulat osušen isti je pomiješan sa 100 g natrij karboksimetilceluloze, 25 g silice, 5 g glicerol palmitostearata i 10 mg talka, nakon čega je sve podvrgnuto kompresiji jedinične težine 495 mg/tableti.
The method according to anyone of claims 1-7, wherein the tumour cells are stem cells. 
Metoda prema zahtjevu 4, naznačena time, što su spomenute tumorske stanice matične stanice.
In some embodiments, the particle is a co-polymer having a molar ratio from about 80:20 to about 100:0. 
Spoj sukladno zahtjevu 1, gdje je čestica kopolimer koji ima molarni omjer od oko 80:20 do oko 100: 0 polilaktička kiselina: poliglikolna kiselina.
Then, the column was pre-equilibrated by flushing through the column 15-20 BV of 20 mM MES pH 5±0.5, conductivity 150±50 µS/cm. pH and conductivity were checked, and washing was continued if the parameters of the column's effluent were out of target values, i.e. pH 5.0±0.5, conductivity 150±50 µS/cm. 
Tada, kolona je bila početno uravnotežena ispiranjem s 15-20 BV 20 mM MES-a, pH 5£#0.5 i provodljivosti od 150+50 uS/cm. pH i provodljivost su bili provjereni, a s ispiranjem je nastavljeno ukoliko su parametri protoka iz kolone bili izvan ciljnih vrijednosti primjerice pH 5.0+0.5, i provodljivosti od 150+50 uS/em.
The first step of Scheme A involves the condensation/cyclisation of the amide compound of formula 1 with a substituted aniline compound in the presence of phosphorus trichloride to obtain the 7-nitro substituted quinazolin-4-one compound of formula 2. 
Prvi stupanj u shemi A uključuje kondenzaciju/ ciklizaciju amidnog spoja formule 1 sa supstituiranim anilinskim spojem u prisutnosti fosfornog triklorida, čime se dobije 7-nitro supstituirani kinazolin-4-on, spoj formule 2.
A further embodiment of the present invention is the use of b) an M3 antagonist of the invention and (a) a PDE4 inhibitor without any other active compound for the preparation of a medicament for simultaneous, concurrent, separate or sequential use in the treatment of a said respiratory disease in a human or animal patient. 
Sljedeće je utjelovljenje predmetnog izuma uporaba b) M3 antagonista sukladno predmetnom izumu i (a) kortikosteroida bez ikakvog drugog djelatnog spoja za pripravu lijeka za istovremenu, paralelnu, odvojenu ili sekvencijalnu uporabu u liječenju respiratornih bolesti koje odgovaraju na M3 antagonizam u bolesnih ljudi ili životinja.
In a further aspect of the invention the polymer fiber is used as an additive in concrete, mortar, plaster, cement or refractory material. 
Upotreba polimernog vlakna u skladu s patentnim zahtjevom 1, naznačena time što je navedeno polimerno vlakno aditiv za beton, žbuku, gips, cement ili vatrostalni materijal.
an antibody which binds to the same epitope as that in DLL3 protein to which any of the antibodies (1) to (4) binds; and 
(5) antitijelo koje se vezuje za isti epitop kao što je onaj što se nalazi u DLL3 proteinu za koji se vezuju bilo koja antitijela od (1) do (4).
second capsule detaching means for actively detaching the capsule (24) from the second jaw member, wherein the first and second detaching means are mechanically coupled with the motor-driven transfer movement of the extraction module. 
- < drugo sredstvo za aktivno odvajanje čahure (24) iz drugog elementa čahure, pri čemu su prvo sredstvo za odvajanje i drugo sredstvo za odvajanje mehanički spojena s kretanjem pri premještanju modula za ekstrakciju, koje kretanje izvodi motor.
A pharmaceutical composition according to claim 8, for treatment of a condition selected from the group consisting of schizophrenia and schizophreniform disorders and bipolar disorder. 
Farmaceutski pripravak prema zahtjevu $, naznačen time, što je za liječenje stanja odabranih iz skupine koja so sastoji od shizofrenije i shizofreničnih poremećaja i bipolarnog poremećaja,
The compound of claim 1 or claim 2 or the pharmaceutical composition of any one of claims 3-7 for use as defined in any one of claims 9-11, wherein the compound or pharmaceutical composition is to be administered intravenously in an amount of no more than 30 µg compound of formula (1) or (2)/kg/minute. 
Farmaceutska kompozicija iz bilo kojeg od patentnih zahtjeva 1 do 7, gdje se farmaceutska kompozicija treba administrirati intravenski u količini koja je u opsegu od 10 µg spoja sa formulom (1)/kg/minuti do 50 µg spoja sa formulom (1)/kg/minuti.
Step 5: Synthesis of compound (h) 
Korak 5 Sinteza spoja (h)
The method of claim 4 or 5 wherein the enucleated nuclear transfer unit cell is an oocyte or an embryonic stem cell. 
Postupak sukladno patentnom zahtjevu 4 ili 5, naznačena time, da je enukicizirana stanična jedinica nuklearnog prijenosa oocit ili embrionalna matična stanica.
a pharmaceutical composition comprising the compound as described in any of clauses (1)-(160) or a pharmaceutically acceptable salt, or prodrug thereof; and at least one pharmaceutically acceptable carrier; 
T 3. Farmaceutski sastav koji se + iz spoja ili farmaceutski prihvatljive soli iz patentnog zahtjeva 1 i najmanje jednog farmaceutski prihvatljivog nosača.
As mouse metastin (A), there are used, for example, (i) a peptide comprising the N-terminal 134th-141st amino acid sequence in the amino acid sequence represented by SEQ ID NO: 3 and consisting of 8 to 52 amino acid residues. 
Derivat metastina prema zahtjevu 1 ili 2, ili njegova sol, naznačen(a) time, da se koristi kao sredstvo za down- regulaciju humanih OT7T175 (metastin receptor) proteina koji se sastoje od amino kiselinske sekvence predstavljene sa SEQ ID NO: 9.
The cocoa powder according to any of claims 1 to 10, wherein the cocoa powder has a fat content of 30% by weight or less, each based on the total weight of the dried cocoa powder. Chocolate or chocolate-like products obtained by a method comprising the steps of: mixing the cocoa powder according to any of claims 1 to 11 with at least one of cocoa aroma, cocoa butter or polyphenolic powder; and 
Postupak proizvodnje čokolade ili čokoladi sličnih proizvoda, naznačen time što se sastoji u koracima: obrade zrna kakaa ili komadića zrna kakaa u skladu s bilo kojim od patentnih zahtjeva 1 do 11, miješanja dobivenog kakaa u prahu s najmanje jednom od kakaove arome, kakaovog maslaca ili polifenolnog praha; i končiranja navedene smjese.
A method according to claim 4 wherein the psychiatric disorder is schizophrenia. 
Uporaba prema zahtjevu 4 naznačena time da psihijatrijski poremećaj je shizofrenija.
The paper product of paragraph 1 or 2, further comprising a second coating comprising a polymer, a metal, an aqueous composition, or a combination thereof. The paper product of paragraphs 1, 2 or 3, further having a first moisture vapour transmission rate (MVTR) greater than a second MVTR of the paper product comprising the paper coating composition devoid of the co-processed microfibrillated cellulose and inorganic particulate material composition. 
Papirni proizvod u skladu s patentnim zahtjevom 8, naznačen time što dodatno sadrži drugu oblogu koja sadrži polimer, metal, vodenu mješavinu, ili njihovu kombinaciju, a dodatno može imati prvu stopu propuštanja vodene pare (MVTR) manju od druge MVTR za papirni proizvod koji ne sadrži suobrađenu mješavinu mikrofibrilirane celuloze i anorganskog partikuliranog materijala.
The method of any one of claims 1-6, wherein the IgG1 antibody comprising a VH region of the amino acid sequence of SEQ ID NO:9 and a VL region of the amino acid sequence of SEQ ID NO:10. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 od 6, naznačen time, da IgG1 protutijelo sadržava VH područje aminokiselinske sekvence SEQ ID NO: 9 1 VL područje aminokiselinske sekvence SEQ ID NO: 10.
The process of claim 1, wherein at least 20 moles, at least 50 moles or at least 100 moles of the boron "ate" complex of formula (II) are provided in step (a). 
Postupak prema patentnom zahtjevu 1, gdje je najmanje 20 mola, najmanje 50 mola ili najmanje 100 mola kompleksa borata formule (77) osigurano u koraku (a).
R6a represents a (C3-C6)cycloalkyl group or a 4 to 6 membered heterocyclyl group which has optionally 1 to 3 substituents independently selected from the substituent group A, or 
a predstavlja (C3-C6)cikloalkil grupu, heteroaril grupu ili 4- do 6- članu heterociklil grupu koja po izboru ima 1 do 3 supstituenta nezavisno odabrana iz supstituentske grupe A], ili
Use of a tumour associated peptide according to any one of Claims 1 to 6 or a nucleic acid according to Claim 7 or 8 or an expression vector according to Claim 9 for the manufacture of a medicament for inducing an immune response, in particular a cellular immune response, more particularly a T-cell mediated immune response against cells of solid tumours which cells express a human class II MHC molecule on their surface and present a polypeptide comprising an amino acid sequence as given in any of Claims 1 to 4. 
Upotreba tumoru pridruženih peptida prema bilo kojem od Zahtjeva 1 do 3 ili nukleinske kiseline prema Zahtjevu 4 staničnog imunološkog odgovora, specifičnije za imunološki odgovor posredovan T limfocitima protiv stanica solidnih tumora koje eksprimiraju humane MHC molekule razreda II na svojoj površini te prikazuju polipeptid koji se sastoji od slijeda aminokiselina navedenog u bilo kojem od Zahljeva 1 ili 2.
Method of producing an aluminium or aluminium alloy strip with a heat-seal lacquer on a first surface and an epoxide based stove lacquer on the second surface, characterised in that a chromium-free conversion coating is produced on the first and second surface of the aluminium or aluminium alloy strip in a continuous production line before applying the heat-seal lacquer and the stove lacquer, the chromium-free conversion coating is produced by 
Postupak proizvodnje aluminijskih traka ili traka od aluminijskih legura s vruće lijepljenim lakom na prvoj površini i s paljenim lakom na bazi epoksida na drugoj površini, naznačen time, da se proizvodi konverzijska obloga bez kroma na prvoj i drugoj površini trake od aluminija ili od aluminijskih legura, u neprekidnoj proizvodnoj liniji prije nanošenja vruće lijepljenog laka i paljenog laka, dok se konverzijska obloga bez kroma proizvodi putem sljedećeg:
characterised in that: said advancement station (32) comprises at least one perforated suction belt (36) for the purpose of stably retaining said sheet (4), 
navedena postaja za pomicanje (32) ima najmanje jednu perforiranu usisnu vrpcu (36), koja služi za stabilno držanje navedenog lista (4), -
An antibody or antigen-binding fragment thereof that specifically binds human interleukin-4 receptor (hIL-4R) for use in a method of treating a disease or disorder, wherein the disease or disorder is improved, ameliorated or inhibited by removal, inhibition or reduction of human interleukin-4 (hIL-4) activity, wherein the antibody or fragment thereof comprises a heavy chain variable region (HCVR) comprising the amino acid sequence shown in SEQ ID NO:162 and a light chain variable region (LCVR) comprising the amino acid sequence shown in SEQ ID NO:164. 
Antitijelo ili njegov fragment koji se vezuje za antigen koji se specifično vezuje za humani interleukin-4 receptor (hIL-4R) (SEQ ID NO:274) za primjenu u metodi liječenja oboljenja ili poremećaja, naznačena time, što je oboljenje ili poremećaj odabran iz skupine koja se sastoji od oboljenja pluća, upalnih poremećaja i alergijskih reakcija, pri čemu antitijelo ili njegov fragment sadrži varijabilnu regiju teškog lanca (HCVR) koja sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NO:162 i varijabilnu regiju lakog lanca (LCVR) koja sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NO:164.
the blade carrier includes first and second grooves therein; and 
nosač oštrica (30) ima u sebi prvi i drugi utor (88, 90); i
A compound for use according to claim 1 wherein the animal to be protected is mammal. 
Uporaba prema zahtjevu 1, naznačena time, da se kod životinje koja se treba zaštititi, radi o stočnim domaćim životinjama.
The compound or salt for use according to claim 16, wherein said myeloproliferative disorder is essential thrombocythemia (ET). 
Farmaceutski sastav za upotrebu prema zahtjevu 21, pri čemu je mijeloproliferativni poremećaj esencijalna trombocitemija (ET).
GKGLEWLSYISGGSSYIFYADSVRGR [SEQ ID NO:29] and wherein the antibody or fragment comprises a variable heavy chain (VH) in which CDR3 comprises or consists of the amino acid sequence of: 
GKGLEWLSYISGGSSYIFYADSVRGR [SEQ ID NQ:29] pri čemu protutijelo ili fragment sadrži varijabilni teški lanac (VH) u kojem CDR3 sadrži ili se sastoji od sekvence amino kiselina:
A process for preparing a compound of formula I-a: wherein Ring A, Ring B and Y are as defined in claim 1, which comprises reducing a compound of formula III: wherein Ring A, Ring B and Y are as defined in claim 1, and R12 is a C1-6 alkyl group. 
€ Riža gdje su Prsten A, Prsten B i Y definirani kao u patentnom zahtjevu 1, a R'* je atom broma ili atom joda, sa spojem boronske kiseline formule X:
the subj etc is not in acute renal failure, 
kod subjekta nije došlo do akutne bubrežne insuficijencije,
coating the tablet cores with the coating suspension to a weight gain of about 2-4 % to produce film-coated tablets. 
oblaganje tabletnih jezgri suspenzijom za oblaganje do dobivanja na težini od oko 2-4% da bi se pripremile film-obložene tablete.
The estrogenic component for use according to any one of claims 1 to 6, wherein the neurological disorder is selected from the group comprising hypoxic brain injury, anoxic brain injury, traumatic brain injury, Alzheimer's disease, and Parkinson's disease. 
Estetrol za upotrebu prema zahtjevu 1 ili 2, naznačen time da je ozljeda mozga odabrana iz skupine koja sadrži hipoksičku ozljedu mozga, anoksičnu ozljedu mozga, traumatsku ozljedu mozga.
After the binding and washing steps, IL-18BP is eluted under certain conditions. 
Nakon vezivanja te nakon koraka ispiranja, IL-1$8BP se eluira u određenim uvjetima.